Equity (Details) $ / shares in Units, $ in Thousands, vaccine_dose in Millions		1 Months Ended
	Mar. 18, 2021 USD ($) vaccine_dose	Aug. 31, 2024 USD ($) shares	Jul. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 01, 2021 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Common stock, par value (in USD per share) | $ / shares			$ 0.01	$ 0.01	$ 0.01
Shares authorized (in shares) | shares			400,000,000
Common stock, shares authorized (in shares) | shares			390,000,000	390,000,000	390,000,000
Preferred stock, shares authorized to issue (in shares) | shares			10,000,000	10,000,000	10,000,000
Convertible preferred stock, par value (in USD per share) | $ / shares			$ 0.01	$ 0.01	$ 0.01
Convertible preferred stock, amount issued | $				$ 0	$ 1		$ 5,000
Convertible preferred stock, amount outstanding | $					$ 4,100	$ 4,100
Level 3 | Discount Rate
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, measurement input							0.15
July 2024 Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold (in shares) | shares			30,400,000
Common stock, par value (in USD per share) | $ / shares			$ 0.01
Price per share of shares issued in underwriting agreement (in USD per share) | $ / shares			$ 1.15
Proceeds from sale of shares issued in underwriting agreement | $			$ 32,300
Over-Allotment Option
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold (in shares) | shares		2,282,608	4,565,217
Option period purchase additional shares in underwriting agreement			30 days
Proceeds from sale of shares issued in underwriting agreement | $		$ 2,400
COVAXIN Preferred Stock Purchase Agreement
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in USD per share) | $ / shares								$ 0.01
Agreement to sell, number of shares issued in transaction (in shares) | shares								100,000
Agreement to sell, price per share (in USD per share) | $ / shares								$ 109.60
Advance payment amount | $	$ 6,000
Conversion ratio (in shares)								10
Supply agreement, number of doses | vaccine_dose	10.0